Trial · NCT03605862
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 28
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time From First Dose to Symptom Response Over 21 Days of Follow up Based Upon the FLU-PRO Instrument (Novel Endpoint) | Nitazoxanide | 122.5 | Inter-Quartile Range 58 to 244 | hours | |
| Time From First Dose to Symptom Response Over 21 Days of Follow up Based Upon the FLU-PRO Instrument (Novel Endpoint) | Placebo | 137.1 | Inter-Quartile Range 75 to 243 | hours | |
| Time From First Dose to Ability to Perform All Normal Activities | Nitazoxanide | 174.3 | Inter-Quartile Range 80 to 340 | hours | |
| Time From First Dose to Ability to Perform All Normal Activities | Placebo | 175.4 | Inter-Quartile Range 105 to 318 | hours | |
| Proportions Experiencing Complications of EV/RV Infection | Nitazoxanide | 12 | Participants | ||
| Proportions Experiencing Complications of EV/RV Infection | Placebo | 20 | Participants | ||
| Time to Return to Usual Health | Nitazoxanide | 154.1 | Inter-Quartile Range 80 to 320 | hours | |
| Time to Return to Usual Health | Placebo | 174.9 | Inter-Quartile Range 104 to 345 | hours | |
| Proportion Positive for EV/RV by RT-PCR at Days 2, 3 and 7 | Nitazoxanide | Day 2 | 0.81 | proportion of participants | |
| Proportion Positive for EV/RV by RT-PCR at Days 2, 3 and 7 | Placebo | Day 2 | 0.81 | proportion of participants | |
| Proportion Positive for EV/RV by RT-PCR at Days 2, 3 and 7 | Nitazoxanide | Day 3 | 0.79 | proportion of participants | |
| Proportion Positive for EV/RV by RT-PCR at Days 2, 3 and 7 | Placebo | Day 3 | 0.79 | proportion of participants | |
| Proportion Positive for EV/RV by RT-PCR at Days 2, 3 and 7 | Nitazoxanide | Day 7 | 0.66 | proportion of participants | |
| Proportion Positive for EV/RV by RT-PCR at Days 2, 3 and 7 | Placebo | Day 7 | 0.76 | proportion of participants | |
| Analysis of Change From Baseline to Days 2, 3 and 7 in EV/RV Virus Titer | Nitazoxanide | Day 2 | -0.2203 | Standard Error 0.0934 | log10 RNA copies/mL |
| Analysis of Change From Baseline to Days 2, 3 and 7 in EV/RV Virus Titer | Placebo | Day 2 | -0.4186 | Standard Error 0.0884 | log10 RNA copies/mL |
| Analysis of Change From Baseline to Days 2, 3 and 7 in EV/RV Virus Titer | Nitazoxanide | Day 3 | -0.5577 | Standard Error 0.1272 | log10 RNA copies/mL |
| Analysis of Change From Baseline to Days 2, 3 and 7 in EV/RV Virus Titer | Placebo | Day 3 | -0.8282 | Standard Error 0.1053 | log10 RNA copies/mL |
| Analysis of Change From Baseline to Days 2, 3 and 7 in EV/RV Virus Titer | Nitazoxanide | Day 7 | -1.5113 | Standard Error 0.1373 | log10 RNA copies/mL |
| Analysis of Change From Baseline to Days 2, 3 and 7 in EV/RV Virus Titer | Placebo | Day 7 | -1.6470 | Standard Error 0.1231 | log10 RNA copies/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03605862/results